A brief period of bilateral carotid occlusion (BCO)-induced forebrain ischemia in gerbils triggers neuronal degeneration and the subsequent expression of amyloid precur sor protein (APP), b-amyloid protein (b-AP), and apolipopro tein E (APO-E) in the selectively vulnerable CAl region of the hippocampus. The increase in immunoreactivity is secondary to the postischemic degeneration of the CAl neurons and is largely astrocyte-derived as evidenced by a simultaneous in crease in glial fibrillary acidic protein (GFAP) staining. Oxy gen radical-induced lipid peroxidation has been strongly sug gested to play a role in postischemic neuronal damage and Alzheimer's disease. Recent literature suggests a possible link between early oxidative stress and APP overexpression. There fore, the present investigation examined the effect of two novel brain-penetrating pyrrolopyrimidine lipid peroxidation inhibi tors (PNU-10 1033E and PNU-104067F) on CAl neurodegen eration and the subsequent increase in APP, b-AP, APO-E, and GFAP immunostaining at 4 days after a 5-minute episode of forebrain ischemia. Using an antibody for lipid peroxidation derived malondialdehyde (MDA)-modified proteins, the au thors also examined the effects of PNU-104067F on MDA immunostaining 2 days after ischemia, before completion of the neuronal loss. At 2 days, the authors also evaluated microglial Amyloid precursor protein (APP) is a large transmem brane glycoprotein which is the source of the b-amyloid (b-AP), a 40-42 amino acid peptide, known to accumu late in the senile plaques and blood vessels in individuals with Alzheimer's disease (AD) (Selkoe, 1993). Deposi tion of b-AP after proteolytic cleavage of APP may play
540 1. A. OOSTVEEN ET AL. 1994) . This seems consistent with the fact that prior head injury is a risk factor for development of AD (Mortimer et aI., 1985; Henderson, 1988; Merz, 1989; Graves et aI., 1990) .
Apolipoprotein E (APO-E), is a 34-kd protein that mediates the clearance of several plasma lipoproteins (Mahley, 1988) and appears in three isoforms (Eb E3, E4)' There is an increased frequency of the E4 allele in sporadic and both early and late-onset familial AD pa tients (Corder et aI., 1993; Houlden et aI., 1993; Poirier, 1993; Saunders et al, 1993) . In vitro experiments indicate that the APO-E4 form, when oxidized, binds to b-AP causing aggregation into amyloid filaments much more rapidly than the more common APO-E3 form (Strittmat ter et aI., 1993a; Sanan et aI., 1994) . These in vitro data suggest that APO-E may play a direct role in b-AP de position and partially explain the association of APO-E4 and AD. Co-localization of APO-E4 and b-AP in the plaques of AD patients support this concept (Namba et aI., 1991) . Using brief forebrain ischemia in gerbils, we have previously shown an increase in APP, b-AP, and APO-E immunoreactivity in the selectively vulnerable CAl region of the hippocampus at 4 days after the isch emic injury (Hall et aI., 1995b , Ali et aI., 1996 . This follows the prior 84% loss of the CAl neurons.
In rodent forebrain ischemia models, there is a signifi cant increase in membrane lipid peroxidation within minutes after reperfusion which continues for several days, and is believed to play a role in the delayed neu ronal damage observed by 4 days after injury (Floyd and Carney, 1991 , Hall et aI., 1993a , Sakamoto et aI., 1991 . Therefore, the present investigation examined the ability of two novel brain-penetrating pyrrolopyrimidine lipid peroxidation inhibitors, PNU-l 01 033E and PNU-104067F (Hall et aI., 1995a; 1997a; Bundy et aI., 1995) ( Fig. I) to decrease delayed postischemic CA I damage and the expression of APP, APO-E, and b-AP. We also evaluated the effects of PNU-I04067F on lipid peroxi dation-derived malondialdehyde (MDA), and microglial activation using immunocytochemical methods. to 60 g were anesthetized with methoxyflurane. A 1-to 2-cm midline throat incision provided access to both carotid arteries, which were clamped with microaneurysm clips. Gerbils were placed in a warming box with an ambient temperature main tained at 37°C via a heating chamber that holds brain tempera ture at 35.5°C for the duration of the bilateral carotid occlusion (BCO) (Hall et al.,1993b) . After 5 minutes of BCO, the clips were removed and reperfusion was allowed for either 48 or 96 hours. The animals remained in the heating chamber until they recovered from anesthesia and could regulate their own body and brain temperatures.
MATERIALS AND METHODS

Tissue preparation
After either 48 or 96 hours of reperfusion (see explanations below), the animals were deeply anesthetized and perfused in-tracardially. Animals were perfused with cold oxygenated Krebs-Ringer bicarbonate, pH 7.2 (Sigma, St. Louis, MO) until the effluent was cleared of blood (2 minutes), followed by perfusion with cold 4% paraformaldehyde in 0. 1 mollL phos phate buffer (pH 7.4) for 8 minutes (approximately 200 mL).
Brains were removed, blocked, and post-fixed for 4 hours at 4°C. Tissues were equilibrated in increasing concentrations of sucrose in phosphate-buffered saline (PBS), pH 7.4 (10,20,30%) over a 3-day period. After complete equilibration in 30% sucrose, the brains were frozen in liquid nitrogen vapor for 10 minutes and stored at -70°C until processing. Brains were sectioned at 25 fLm on a Leitz sledge microtome with a freezing stage into 0.0 1 mollL PBS at 4°C (pH 7.4). The sec tions were mounted on gelatin-coated slides and air dried.
Immunocytochemical procedures
After rinsing in 0.0 I mollL PBS pH 7.4 (buffer), endogenous hours. After a 10-minute buffer rinse, slides were incubated for 1 hour in the Vectastain Elite ABC Reagent according to rec ommended procedures. Immunocytochemical controls were also run for sham and each of the postischemic time points that were only exposed to the secondary antibody. After a 10minute buffer rinse, the immunoreactivity was visualized by incubation for 4.5 minutes in the ABC peroxidase substrate solution with nickel chloride added for the computer-assisted densitometric analysis. Slides were rinsed in ddH20, dehy drated in increasing concentrations of ethanol, cleared in xy lene, and mounted in DPX.
Neuronal cell counts
For the investigation of the effects of PNU-10 1033E and PNU-104067F on hippocampal CAl neuronal preservation, a 96-hour time point was selected. This was based on our previ ous demonstration that postischemic CAl degeneration with the gerbil forebrain ischemia model in our hands is complete by 72 hours (i.e., it is not greater at either 48 or 168 hours) (Hall et aI., 1995b) . The animals were treated with either PNU-10 1033E days. The doses were selected based on the previous demon stration of their protective efficacy (Hall et ai., 1995 a; 1997a) .
A group of untreated, nonischemic (sham) animals (n = 9) was also included as a control. Numbers of normal appearing me dial CAl neurons were blindly counted in sham, vehicle, and drug-treated animals in 25-fLm sections stained with cresyl vio-let. The number of neuronsJ3 15 mm was counted in the medial CAl region and averaged for the two hemispheres.
MDA and microglial immunocytochemical analysis
For the investigation of effects of PNU-104067F on MDA immunostaining and microglial activation, animals were treated with vehicle (n=8), PNU-104067F (n=8), or sham (n=7) using the same protocol except that sacrifice occurred at 48 hours after injury. This time point was selected for two reasons.
The first is that both microglial activation (Morioka et aI., 199 1; Gehrmann et aI., 1992) and MDA immunostaining (Hall et aI., 1997b) are significantly increased by 48 hours after brief forebrain ischemia, thus constituting an adequately developed end point for drug therapy. The second reason is that we wanted to investigate drug effects on these parameters at a time that attached to an Olympus microscope. A 96-hour postischemic time was selected for these studies based on the prior demon stration that these parameters are significantly and maximally increased by that point (Hall et aI., 1995b) . The immunostained areas of the digitized CAl region of the hippocampus were outlined. The adjacent nonimmunostained area representing the background was outlined separately. The optical density (OD) of each of these areas was calculated by subtracting the OD of the adjacent background from the OD for the CAl area. For each animal, the background-corrected OD was taken for the right and left CAl sector and the mean used as the value for that animal. The output of the video camera was determined to be linear over the range of the OD measured in this study. A normalizing function was applied to correct for variation in intensity of illumination between sections.
Statistical analysis
All data are expressed as mean ± SD. Differences in CAl neuronal counts and each of the immunocytochemical end points between sham-operated (nonischemic) and postischemic animals were statistically evaluated using a one-way analysis of variance with a P < .05 required for significance.
RESULTS
Effects on 96-hour postischemic CAl neuronal damage Figure 3 shows that by 96 hours after ischemia, there
is an 84% loss of medial CAl neurons in the vehicle treated animals (sham = 82.6 ± 11.8, vehicle-treated o ischemic = 13.2 ± 15.5 neurons/315 /-Lm). This is con sistent with previously published reports concerning the loss of neurons in the CAl region after a 5-minute isch emic gerbil injury (Kirino, 1982; Hall et aI., 1995a, b) .
Both PNU-IOl033E and PNU-104067F provided signifi cant protection against neuronal loss. The former attenu ated the CAl damage to 44% and the latter decreased it to 60%. Figure 4 is a cresyl violet-stained photomicro graph depicting the effects of PNU-I04067F on CAl neuronal cell loss 96 hours days after 5 minutes of fore brain ischemia.
Effects on 48-hour postischemic
MDA immunoreactivity
At 48 hours after a 5-minute period of forebrain isch emia, the CAl neuronal loss is approximately 50% (data not shown). 
DISCUSSION
The present investigation has shown the ability of two novel brain-penetrating lipid-peroxidation-inhibiting pyrrolopyrimidines, PNU-101033E and PNU-104067F, to significantly attenuate delayed postischemic hippo campal CAl neuronal loss as well as APP, b-AP, APO-E, and GFAP immunostaining. PNU-1 01033E has been previously shown to decrease infarct size in mice after permanent middle cerebral artery occlusion (Hall et aI., 1995a) , to lessen hippocampal CAl necrosis in the gerbil 5-minute forebrain ischemia model (Hall et aI., 1995a) , and to decrease cortical necrosis in the neonatal rat hyp oxic-ischemic brain injury model (Fleck and Hall, 1995) . and Carney, 1991; Hall et aI., 1993a; Hall, 1996) . While the present mechanistically oriented study used pre ischemic treatment, prior work has shown that, at least for PNU-101033E, postischemic administration begin ning as late as 4 hours after reperfusion still results in significant neuroprotection in the gerbil 5-minute fore brain ischemia model (Hall et aI., 1995a) .
In the forebrain ischemia model, there are increases in oxygen radical formation and membrane lipid peroxida tion, as well as disturbances in membrane function within the first minutes after reperfusion which precede delayed CAl neuronal death (Floyd and Carney, 1991; Hall et aI., 1993a; Kirino et aI., 1993) . The increased level of lipid peroxidation persists for several days after brief forebrain ischemia (Floyd and Carney, 1991) . The There are several potential sources of oxygen radicals in ischemic brain (Hall, 1996) . The neuronal changes that result from ischemia are accompanied by microglial activation which may contribute to postischemic free radical production (Colton and Gilbert, 1987) . Microglial activation has been documented previously to be an early event in the CA I region of rats subjected to brief fore brain ischemia (Morioka et aI., 1991 ; Gehrmann et aI., 1992) , and microglia are perhaps the initial responding Moreover, the fact that a lipid peroxidation inhibitor can suppress microglial activation suggests that lipid peroxi dation products may play a role in triggering microglial activation although this possibility requires further study.
In addition to the potential significance of the present study to selective neuronal vulnerability in the context of brief global ischemia, the current results may also have relevance to AD. First of all, within the hippocampus, selective CAl degeneration, as observed after brief fore brain ischemia, is also seen in AD brains (West et aI., 1994) . Thus, CAl protective efficacy in the gerbil model may be relevant to the possibility of CAl neuronal pres ervation in AD. Second, oxygen radicals and lipid per oxidation have recently been suggested to play a role in the development of AD. Support for this view includes the findings that (1) brain reactive oxygen levels increase with age (Blass, 1993); (2) antioxidant enzymes such as superoxide dismutase are altered in AD brains (Pappolla et aI., 1992) ; (3) there is an increase in lipid peroxidation products in the brains of AD patients (Subbarao et aI., 1990; Gatz et aI., 1992) ; (4) the AD brain is more sus ceptible to lipid peroxidative processes (Subbarao et aI., 1990; Gatz et aI., 1992) ; and (5) there is an increased level of total iron in various regions of AD brains which can drive lipid peroxidation reactions (Richardson, 1993 (Hall et aI., 1995b) .
Astrocyte proliferation, as evidenced by increases in GFAP, has also been documented in the hippocampus after ischemia (Petito et aI., 1990; Schmidt-Kastner et aI., 1990 , Hall et aI., 1995b , as confirmed in the present experiments. The coincidence of astrocytic activation and the APO-E increase suggest that astrocytes are the 1. A. OOSTVEEN ET AL.
main source of APO-E (Boyles et aI., 1985; Pitas et aI., 1987) . Astrocytes are the main source of APO-E in the brain, and studies have shown a relationship between increased astrocytic activation and the levels of hippo campal APO-E mRNA after injury-induced degeneration (Ignatius et ai., 1986; Poirier et aI., 1991 ; Poirier et aI., 1993; Ali et ai., 1996) . It has been suggested that APO-E may play a role in the post-traumatic neuronal repair by increasing lipid transport. Thus, the postischemic expres sion of APO-E, similar to that of APP discussed earlier, could represent a repair or a trophic response. Alterna tively, the increased production of certain APO-E iso forms coincident with increased b-AP could conceivably be detrimental (Strittmatter et aI., 1993a; 1993b; 1994) .
This latter possibility seems more relevant to the current results because the increase in APO-E does not occur until after CAl degeneration is complete.
In summary, the pyrrolopyrimidine lipid peroxidation 
